Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease

Inflammatory Bowel Diseases

Volumn 21, Issue 12, 2015, Pages 2806-2814

  Gibson, David J ^a   Elliott, Louise ^a   McDermott, Edel ^a   Tosetto, Miriam ^a   Keegan, Denise ^a   Byrne, Kathryn ^a   Martin, Sean T ^a   Rispens, Theo ^b   Cullen, Garret ^a   Mulcahy, Hugh E ^a   Cheifetz, Adam S ^a,c   Moss, Alan C ^c   Robson, Simon C ^c   Doherty, Glen A ^a,c   Ryan, Elizabeth J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD39; Crohn's disease; T regulatory cells; Th17; therapeutic drug levels; ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; C REACTIVE PROTEIN; CD39 ANTIGEN; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; ANTIINFLAMMATORY AGENT; APYRASE; GASTROINTESTINAL AGENT; IL17A PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; EXPERIMENTAL COLITIS; FEMALE; FLOW CYTOMETRY; GENE DELETION; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; COLITIS, ULCERATIVE; CROHN DISEASE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MOUSE; PROSPECTIVE STUDY; YOUNG ADULT;

ADALIMUMAB; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APYRASE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; INTERLEUKIN-17; MALE; MICE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84948144960     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000566     Document Type: Article

References (26)

1. Neish AS. Microbes in gastrointestinal health and disease. Gastroenter-ology. 2009;136:65-80.
2. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4 +CD25+ regulatory T cells. J Immunol. 2003;170:3939-3943.
3. Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with Refractory Crohn's disease. Gastroenterology. 2012;143:1207-1217.
4. Boschetti G, Nancey S, Sardi F, et al. Therapy with anti-TNFa antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:160-170.
5. Veltkamp C, Anstaett M, Wahl K, et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFa treatment. Gut. 2011;60:1345-1353.
6. Gibson DJ, Ryan EJ, Doherty GA. Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2716-2724.
7. Dwyer KM, Deaglio S, Gao W, et al. CD39 and control of cellular immune responses. Purinergic Signal. 2007;3:171-180.
8. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257-1265.
9. Roederer M, Quaye L, Mangino M, et al. The genetic architecture of the human immune system: a bioresource for autoimmunity and disease path-ogenesis. Cell. 2015;161:387-403.
10. Fletcher JM, Lonergan R, Costelloe L, et al. CD39(+)Foxp3(+) regulatory T cells suppress pathogenic Th17 cells and are Impaired in multiple sclerosis. J Immunol. 2009;183:7602-7610.
11. Dwyer KM, Hanidziar D, Putheti P, et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant. 2010;10:2410-2420.
12. Friedman DJ, Kunzli BM, A-Rahim YI, et al. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci USA. 2009;106:16788-16793.
13. Gagliani N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19:739-746.
14. Magnani CF, Alberigo G, Bacchetta R, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol. 2011;41:1652-1662.
15. McDermott E, Keegan D, Byrne K, et al. The Short Health Scale: a valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients. J Crohns Colitis. 2013;7:616-621.
16. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74:513-518.
17. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36:765-771.
18. Ostanin DV, Bao J, Koboziev I, et al. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296:G135-G146.
19. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
20. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastro-enterology. 2005;128:1868-1878.
21. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010;30:80-89.
22. Hovhannisyan Z, Treatman J, Littman DR, et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011; 140:957-965.
23. Hoechst B, Gamrekelashvili J, Manns MP, et al. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011;117:6532-6541.
24. Kaneider NC, Egger P, Dunzendorfer S, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol. 2002;22:894-900.
25. Di Sabatino A, Biancheri P, Piconese S, et al. Peripheral regulatory T cells and serum transforming growth factor-beta: relationship with clinical response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2010;16:1891-1897.
26. Canavan JB, Scotta C, Vossenkamper A, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut. [published online ahead of print February 24, 2015]. doi: 10.1136/gutjnl-2014-306919.